NEW YORK (TheStreet) -- Achillion Pharmaceuticals (ACHN) touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target on Monday in the wake of Roche's $8.3 billion bid for InterMune (ITMN) .
The deal led the biotech sector up on Monday and UBS highlighted Achillion as another potential merger and acquisition target.
"While we had viewed InterMune as a top take-out candidate in biotech, we also note our Buy rating on Achillion Pharmaceuticals shares also reflects M&A potential," the firm wrote, according to Barron's.
Must Read: Warren Buffett's 25 Favorite Stocks
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.